{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:29:49Z","timestamp":1762522189781,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1172544"],"award-info":[{"award-number":["OPP1172544"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2846-6","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T14:18:34Z","timestamp":1535033914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Patrick","family":"Nachipo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Quinnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melita A.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley C.","family":"Van Voorhis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3682-8892","authenticated-orcid":false,"given":"Pui-Ying","family":"Iroh Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"2846_CR1","doi-asserted-by":"publisher","first-page":"e0004729","DOI":"10.1371\/journal.pntd.0004729","volume":"10","author":"SO Sow","year":"2016","unstructured":"Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. The burden of Cryptosporidium diarrheal disease among children < 24 months of age in moderate\/high mortality regions of sub-Saharan Africa and South Asia, utilizing data from the global enteric multicenter study (GEMS). PLoS Negl Trop Dis. 2016;10:e0004729.","journal-title":"PLoS Negl Trop Dis"},{"key":"2846_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15:85\u201394.","journal-title":"Lancet Infect Dis"},{"key":"2846_CR3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","volume":"360","author":"B Amadi","year":"2002","unstructured":"Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360:1375\u201380.","journal-title":"Lancet"},{"key":"2846_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0035-9203(98)90804-5","volume":"92","author":"JF Rossignol","year":"1998","unstructured":"Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg. 1998;92:663\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2846_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2036.2005.02394.x","volume":"21","author":"I Zulu","year":"2005","unstructured":"Zulu I, Kelly P, Njobvu L, Sianongo S, Kaonga K, McDonald V, et al. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial. Aliment Pharmacol Ther. 2005;21:757\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"2846_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2334-9-195","volume":"9","author":"B Amadi","year":"2009","unstructured":"Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis. 2009;9:195.","journal-title":"BMC Infect Dis"},{"key":"2846_CR7","doi-asserted-by":"publisher","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","volume":"11","author":"MS Love","year":"2017","unstructured":"Love MS, Beasley FC, Jumani RS, Wright TM, Chatterjee AK, Huston CD, et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl Trop Dis. 2017;11:e0005373.","journal-title":"PLoS Negl Trop Dis"},{"key":"2846_CR8","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1128\/AAC.00260-15","volume":"59","author":"RV Swanson","year":"2015","unstructured":"Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015;59:3042\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"2846_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","volume":"67","author":"MC Cholo","year":"2012","unstructured":"Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67:290\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2846_CR10","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"T Yano","year":"2011","unstructured":"Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011;286:10276\u201387.","journal-title":"J Biol Chem"},{"key":"2846_CR11","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1128\/AAC.36.12.2729","volume":"36","author":"CE Van Rensburg","year":"1992","unstructured":"Van Rensburg CE, Joone GK, O'Sullivan JF, Anderson R. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother. 1992;36:2729\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"2846_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/jac\/dkh215","volume":"53","author":"MC Bopape","year":"2004","unstructured":"Bopape MC, Steel HC, Cockeran R, Matlola NM, Fourie PB, Anderson R. Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases. J Antimicrob Chemother. 2004;53:971\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"2846_CR13","first-page":"133","volume":"44","author":"NE Morrison","year":"1976","unstructured":"Morrison NE, Marley GM. The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976;44:133\u20134.","journal-title":"Int J Lepr Other Mycobact Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2846-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:26:18Z","timestamp":1589541978000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2846-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2846"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2846-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent by the participants older than 18\u00a0years of age will be obtained from the participants\u2019 guardians if they are illiterate. The trial was approved by NHSRC (reference 17\/05\/1821) on 28 July 2017, and by the Liverpool School of Tropical Medicine Research Ethics Committee (reference 17\u2013031) on 15 November 2017. The University of Washington did not require additional approval. Approval for conducting the clinical trial and for importation of the study investigational products was obtained from PMPB (28 November 2017; reference PMPB\/CTRC\/2A\/CFZ-001).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"456"}}